Iranian Journal of Child Neurology

Picard C, Gaspar HB, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee report on inborn errors of immunity. Journal of clinical immunology. 2018;38(1):96-128.

Samarghitean C, Ortutay C, Vihinen M. Systematic classification of primary immunodeficiencies based on clinical, pathological, and laboratory parameters. The Journal of Immunology. 2009;183(11):7569-75.

Bousfiha A, Jeddane L, Picard C, Ailal F, Gaspar HB, Al-Herz W, et al. The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies. Journal of clinical immunology. 2018;38(1):129-43.

Aydin ÖF, Anlar B. Neurological Manifestations of Primary Immunodeficiency Diseases. Clinical pediatrics. 2017:0009922817737083.

M B, HK L. Approach to the patient with recurrent infections. In: NF AJ, BS B, W B, WW B, ST H, RF LJ, et al., editors. Middleton's Allergy Principles &Practice. 2. 8th ed. Philadelphia: Elsevier Saunders; 2014. p. 1140.

Whitmore KV, Gaspar HB. Adenosine deaminase deficiency–more than just an immunodeficiency. Frontiers in immunology. 2016;7:314.

Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD. How I treat ADA deficiency. Blood. 2009;114(17):3524-32.

Dehkordy SF, Aghamohammadi A, Ochs HD, Rezaei N. Primary immunodeficiency diseases associated with neurologic manifestations. Journal of clinical immunology. 2012;32(1):1-24.

Nofech-Mozes Y, Roifman C. Neurological manifestations in severe combined immunodeficiency secondary to adenosine deaminase deficiency: Three case reports and review of the literature. Journal of Allergy and Clinical Immunology. 2005;115(2):S78.

Chistiakov DA, Voronova NV, Chistiakov AP. Ligase IV syndrome. European journal of medical genetics. 2009 Nov-Dec;52(6):373-8. PubMed PMID: 19467349. Epub 2009/05/27. eng.

IJspeert H, Warris A, Flier M, Reisli I, Keles S, Chishimba S, et al. Clinical spectrum of LIG4 deficiency is broadened with severe dysmaturity, primordial dwarfism, and neurological abnormalities. Human mutation. 2013;34(12):1611-4.

Enders A, Fisch P, Schwarz K, Duffner U, Pannicke U, Nikolopoulos E, et al. A severe form of human combined immunodeficiency due to mutations in DNA ligase IV. The Journal of Immunology. 2006;176(8):5060-8.

Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016 Nov 25;11(1):159. PubMed PMID: 27884168. Pubmed Central PMCID: PMC5123280. Epub 2016/11/26. eng.

Frappart P-O, McKinnon PJ. Ataxia-telangiectasia and related diseases. Neuromolecular medicine. 2006;8(4):495-511.

Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, Carson KA, Lederman HM. Immunodeficiency and infections in ataxia-telangiectasia. The Journal of pediatrics. 2004;144(4):505-11.

Lockman JL, Iskander AJ, Bembea M, Crawford TO, Lederman HM, McGrath-Morrow S, et al. The critically ill patient with ataxia–telangiectasia: A case series. Pediatric Critical Care Medicine. 2012;13(2):e84-e90.

Schroeder SA, Zielen S. Infections of the respiratory system in patients with ataxia-telangiectasia. Pediatric pulmonology. 2014 Apr;49(4):389-99. PubMed PMID: 23761391. Epub 2013/06/14. eng.

Crawford T, Skolasky R, Fernandez R, Rosquist K, Lederman H. Survival probability in ataxia telangiectasia. Archives of disease in childhood. 2006;91(7):610-1.

Kraus M, Lev A, Simon AJ, Levran I, Nissenkorn A, Levi YB, et al. Disturbed B and T cell homeostasis and neogenesis in patients with ataxia telangiectasia. J Clin Immunol. 2014 Jul;34(5):561-72. PubMed PMID: 24789685. Epub 2014/05/03. eng.

Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangiectasia: diagnosis and treatment. Seminars in pediatric neurology. 2003 Sep;10(3):173-82. PubMed PMID: 14653405. Epub 2003/12/05. eng.

Chrzanowska KH, Gregorek H, Dembowska-Baginska B, Kalina MA, Digweed M. Nijmegen breakage syndrome (NBS). Orphanet J Rare Dis. 2012 Feb 28;7:13. PubMed PMID: 22373003. Pubmed Central PMCID: PMC3314554. Epub 2012/03/01. eng.

Distel L, Neubauer S, Varon R, Holter W, Grabenbauer G. Fatal toxicity following radio‐and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen Breakage Syndrome. Pediatric Blood & Cancer. 2003;41(1):44-8.

Wegner R-D, German JJ, Chrzanowska KH, Digweed M, Stumm M. Chromosomal instability syndromes other than ataxia-telangiectasia. Primary immunodeficiency diseases A molecular and genetic approach. 2007;2.

Bekiesinska-Figatowska M, Chrzanowska KH, Jurkiewicz E, Wakulinska A, Rysiewskis H, Gladkowska-Dura M, et al. Magnetic resonance imaging of brain abnormalities in patients with the Nijmegen breakage syndrome. Acta neurobiologiae experimentalis. 2004;64(4):503-9. PubMed PMID: 15586667. Epub 2004/12/14. eng.

Ehrlich M, Jackson K, Weemaes C. Immunodeficiency, centromeric region instability, facial anomalies syndrome (ICF). Orphanet journal of rare diseases. 2006;1(1):2.

Jin B, Tao Q, Peng J, Soo HM, Wu W, Ying J, et al. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function. Human molecular genetics. 2007;17(5):690-709.

Hagleitner M, Lankester A, Maraschio P, Hulten M, Fryns J-P, Schuetz C, et al. Clinical spectrum of immunodeficiency, centromeric instability and facial dysmorphism (ICF syndrome). Journal of medical genetics. 2008;45(2):93-9.

Blundred RM, Stewart GS. DNA double-strand break repair, immunodeficiency and the RIDDLE syndrome. Expert review of clinical immunology. 2011;7(2):169-85.

DA D, KE S. DiGeorge Syndrome: a chromosome 22q11.2 deletion syndrome. In: Ochs HD SC, Puck JM, editor. Primary Immunodeficiency Diseases A Molecular and Genetic Approach. 3rd ed. New York: Oxford University Press; 2014. p. 580-92.

Gothelf D, Schaer M, Eliez S. Genes, brain development and psychiatric phenotypes in velo‐cardio‐facial syndrome. Developmental disabilities research reviews. 2008;14(1):59-68.

Kim E-H, Yum M-S, Lee B-H, Kim H-W, Lee H-J, Kim G-H, et al. Epilepsy and other neuropsychiatric manifestations in children and adolescents with 22q11. 2 deletion syndrome. Journal of Clinical Neurology. 2016;12(1):85-92.

Schaer M, Eliez S. From genes to brain: understanding brain development in neurogenetic disorders using neuroimaging techniques. Child and Adolescent Psychiatric Clinics. 2007;16(3):557-79.

Kinoshita H, Kokudo T, Ide T, Kondo Y, Mori T, Homma Y, et al. A patient with DiGeorge syndrome with spina bifida and sacral myelomeningocele, who developed both hypocalcemia-induced seizure and epilepsy. Seizure-European Journal of Epilepsy. 2010;19(5):303-5.

Yang L, Fliegauf M, Grimbacher B. Hyper-IgE syndromes: reviewing PGM3 deficiency. Current opinion in pediatrics. 2014;26(6):697-703.

Freeman AF, Holland SM. Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes. Pediatric research. 2009;65(5):32R.

Renner ED, Puck JM, Holland SM, Schmitt M, Weiss M, Frosch M, et al. Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. The Journal of pediatrics. 2004;144(1):93-9.

Freeman AF, Holland SM. Clinical manifestations of hyper IgE syndromes. Disease markers. 2010;29(3, 4):123-30.

Yavuz H, Chee R. A review on the vascular features of the hyperimmunoglobulin E syndrome. Clinical & Experimental Immunology. 2010;159(3):238-44.

Rael EL, Marshall RT, McClain JJ. The hyper-IgE syndromes: lessons in nature, from bench to bedside. World Allergy Organization Journal. 2012;5(7):79.

Ghaffari J, Ahanchian H, Zandieh F. Update on Hyper IgE syndrome (HIES). Journal of Pediatrics Review. 2014;2(1):39-46.

Zhang Y, Yu X, Ichikawa M, Lyons JJ, Datta S, Lamborn IT, et al. Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. The Journal of allergy and clinical immunology. 2014 May;133(5):1400-9, 9 e1-5. PubMed PMID: 24589341. Pubmed Central PMCID: PMC4016982. Epub 2014/03/05. eng.

Kilic SS, Donmez O, Sloan EA, Elizondo LI, Huang C, André JL, et al. Association of migraine‐like headaches with Schimke immuno‐osseous dysplasia. American Journal of Medical Genetics Part A. 2005;135(2):206-10.

Clewing JM, Antalfy BC, Lucke T, Najafian B, Marwedel KM, Hori A, et al. Schimke immuno-osseous dysplasia: a clinicopathological correlation. J Med Genet. 2007 Feb;44(2):122-30. PubMed PMID: 16840568. Pubmed Central PMCID: PMC2598061. Epub 2006/07/15. eng.

Deguchi K, Clewing JM, Elizondo LI, Hirano R, Huang C, Choi K, et al. Neurologic phenotype of Schimke immuno-osseous dysplasia and neurodevelopmental expression of SMARCAL1. Journal of Neuropathology & Experimental Neurology. 2008;67(6):565-77.

Vulliamy T, Dokal I. Dyskeratosis congenita: the diverse clinical presentation of mutations in the telomerase complex. Biochimie. 2008;90(1):122-30.

Glousker G, Touzot F, Revy P, Tzfati Y, Savage SA. Unraveling the pathogenesis of Hoyeraal–Hreidarsson syndrome, a complex telomere biology disorder. British journal of haematology. 2015;170(4):457-71.

Pearson T, Curtis F, Al‐Eyadhy A, Al‐Tamemi S, Mazer B, Dror Y, et al. An intronic mutation in DKC1 in an infant with Høyeraal–Hreidarsson syndrome. American Journal of Medical Genetics Part A. 2008;146(16):2159-61.

Yeates L, Slatter MA, Gennery AR. Infusion of Sibling Marrow in a Patient with Purine Nucleoside Phosphorylase Deficiency Leads to Split Mixed Donor Chimerism and Normal Immunity. Frontiers in pediatrics. 2017;5:143.

La Marca G, Canessa C, Giocaliere E, Romano F, Malvagia S, Funghini S, et al. Diagnosis of immunodeficiency caused by a purine nucleoside phosphorylase defect by using tandem mass spectrometry on dried blood spots. Journal of Allergy and Clinical Immunology. 2014;134(1):155-9. e3.

Ozkinay F, Pehlivan S, Onay H, van den Berg P, Vardar F, Koturoglu G, et al. Purine nucleoside phosphorylase deficiency in a patient with spastic paraplegia and recurrent infections. Journal of child neurology. 2007;22(6):741-3.

T R, M W. Hepatic veno-occlusive disease with immunodeficiency. In: Ochs H, Smith CIE, Puck JM editor. Primary Immunodeficiency DiseasesA molecular and genetic approach. 3rd ed. New York: Oxford University Press; 2014. p. 501-8.

Cullup T, Kho AL, Dionisi-Vici C, Brandmeier B, Smith F, Urry Z, et al. Recessive mutations in EPG5 cause Vici syndrome, a multisystem disorder with defective autophagy. Nature genetics. 2013;45(1):83.

Finocchi A, Angelino G, Cantarutti N, Corbari M, Bevivino E, Cascioli S, et al. Immunodeficiency in Vici syndrome: a heterogeneous phenotype. American Journal of Medical Genetics Part A. 2012;158(2):434-9.

Larner A, Webster A, Thomas D. Peripheral neuropathy associated with common variable immunodeficiency. European Journal of neurology. 2000;7(5):573-5.

Ozdemir O, Okan MS, Kilic SS. Chronic inflammatory demyelinating polyneuropathy in common variable immunodeficiency. Pediatric neurology. 2012 Apr;46(4):260-2. PubMed PMID: 22490776. Epub 2012/04/12. eng.

Nguyen JT-U, Green A, Wilson MR, DeRisi JL, Gundling K. Neurologic complications of common variable immunodeficiency. Journal of clinical immunology. 2016;36(8):793-800.

Novo A, Carvalho P, Nogueira A, Pita J, Constanço C, Vieira F, et al. Neurological complications of common variable immunodeficiency: the immune system in chaos. 2016.

Aslam A, Misbah S, Talbot K, Chapel H. Vitamin E deficiency induced neurological disease in common variable immunodeficiency: two cases and a review of the literature of vitamin E deficiency. Clinical immunology. 2004;112(1):24-9.

Jolles S. The variable in common variable immunodeficiency: a disease of complex phenotypes. The Journal of Allergy and Clinical Immunology: In Practice. 2013;1(6):545-56.

CIE S, ME C. X-linked agammaglobulinemia and autosomal recessive agammaglobulinemia. In: Ochs H, Smith CIE,Puck JM, editor. Primary Immunodeficiency DiseasesA molecular and genetic approach. 3rd ed. New York: Oxford University Press; 2014. p. 299-323.

Quartier P, Foray S, Casanova J-L, Hau-Rainsard I, Blanche S, Fischer A. Enteroviral meningoencephalitis in X-linked agammaglobulinemia: intensive immunoglobulin therapy and sequential viral detection in cerebrospinal fluid by polymerase chain reaction. The Pediatric infectious disease journal. 2000;19(11):1106-8.

Sag AT, Saka E, Ozgur TT, Sanal O, Ayvaz DC, Elibol B, et al. Progressive neurodegenerative syndrome in a patient with X-linked agammaglobulinemia receiving intravenous immunoglobulin therapy. Cognitive and Behavioral Neurology. 2014;27(3):155-9.

Kaplan J, De Domenico I, Ward DM. Chediak-Higashi syndrome. Current opinion in hematology. 2008 Jan;15(1):22-9. PubMed PMID: 18043242. Epub 2007/11/29. eng.

Tardieu M, Lacroix C, Neven B, Bordigoni P, de Saint Basile G, Blanche S, et al. Progressive neurologic dysfunctions 20 years after allogeneic bone marrow transplantation for Chediak-Higashi syndrome. Blood. 2005;106(1):40-2.

Dotta L, Parolini S, Prandini A, Tabellini G, Antolini M, Kingsmore SF, et al. Clinical, laboratory and molecular signs of immunodeficiency in patients with partial oculo-cutaneous albinism. Orphanet journal of rare diseases. 2013;8(1):168.

Jung J, Bohn G, Allroth A, Boztug K, Brandes G, Sandrock I, et al. Identification of a homozygous deletion in the AP3B1 gene causing Hermansky-Pudlak syndrome, type 2. Blood. 2006;108(1):362-9.

Wenham M, Grieve S, Cummins M, Jones ML, Booth S, Kilner R, et al. Two patients with Hermansky Pudlak syndrome type 2 and novel mutations in AP3B1. haematologica. 2010;95(2):333-7.

Ammann S, Schulz A, Krägeloh-Mann I, Dieckmann NM, Niethammer K, Fuchs S, et al. Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome. Blood. 2016;127(8):997-1006.

Badolato R, Parolini S. Novel insights from adaptor protein 3 complex deficiency. Journal of allergy and clinical immunology. 2007;120(4):735-41.

Decaminada N, Cappellini M, Mortilla M, Del Giudice E, Sieni E, Caselli D, et al. Familial hemophagocytic lymphohistiocytosis: clinical and neuroradiological findings and review of the literature. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 2010 Jan;26(1):121-7. PubMed PMID: 19649640. Epub 2009/08/04. eng.

Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert review of clinical immunology. 2010;6(1):137-54.

Guo C, Nakazawa Y, Woodbine L, Björkman A, Shimada M, Fawcett H, et al. XRCC4 deficiency in human subjects causes a marked neurological phenotype but no overt immunodeficiency. Journal of Allergy and Clinical Immunology. 2015;136(4):1007-17.

Kim M-M, Yum M-S, Choi H-W, Ko T-S, Im HJ, Seo J-J, et al. Central nervous system (CNS) involvement is a critical prognostic factor for hemophagocytic lymphohistiocytosis. The Korean journal of hematology. 2012;47(4):273-80.

Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr. 2007 Feb;166(2):95-109. PubMed PMID: 17151879. Epub 2006/12/08. eng.

Song E, Jaishankar GB, Saleh H, Jithpratuck W, Sahni R, Krishnaswamy G. Chronic granulomatous disease: a review of the infectious and inflammatory complications. Clinical and Molecular Allergy. 2011;9(1):10.

Finocchi A, Claps A, Serafinelli J, Salfa I, Longo D, Di Matteo G, et al. Chronic granulomatous disease presenting with salmonella brain abscesses. The Pediatric infectious disease journal. 2014;33(5):525-8.

Carlsson G, Van’t Hooft I, Melin M, Entesarian M, Laurencikas E, Nennesmo I, et al. Central nervous system involvement in severe congenital neutropenia: neurological and neuropsychological abnormalities associated with specific HAX1 mutations. Journal of internal medicine. 2008;264(4):388-400.

Germeshausen M, Grudzien M, Zeidler C, Abdollahpour H, Yetgin S, Rezaei N, et al. Novel HAX1 mutations in patients with severe congenital neutropenia reveal isoform-dependent genotype-phenotype associations. Blood. 2008;111(10):4954-7.

Rezaei N, Chavoshzadeh Z, Alaei O, Sandrock I, Klein C. Association of HAX1 deficiency with neurological disorder. Neuropediatrics. 2007;38(05):261-3.

Boocock GR, Morrison JA, Popovic M, Richards N, Ellis L, Durie PR, et al. Mutations in SBDS are associated with Shwachman–Diamond syndrome. Nature genetics. 2003;33(1):97.

Kerr EN, Ellis L, Dupuis A, Rommens JM, Durie PR. The behavioral phenotype of school-age children with shwachman diamond syndrome indicates neurocognitive dysfunction with loss of Shwachman-Bodian-Diamond syndrome gene function. The Journal of pediatrics. 2010;156(3):433-8. e1.

Toiviainen‐Salo S, Mäkitie O, Mannerkoski M, Hämäläinen J, Valanne L, Autti T. Shwachman–Diamond syndrome is associated with structural brain alterations on MRI. American Journal of Medical Genetics Part A. 2008;146(12):1558-64.

Gazit Y, Mory A, Etzioni A, Frydman M, Scheuerman O, Gershoni-Baruch R, et al. Leukocyte adhesion deficiency type II: long-term follow-up and review of the literature. J Clin Immunol. 2010 Mar;30(2):308-13. PubMed PMID: 20099014. Epub 2010/01/26. eng.

Yakubenia S, Wild MK. Leukocyte adhesion deficiency II. The FEBS journal. 2006;273(19):4390-8.

Etzioni A, Tonetti M. Leukocyte adhesion deficiency II–from A to almost Z. Immunological reviews. 2000;178(1):138-47.

Moulding DA, Record J, Malinova D, Thrasher AJ. Actin cytoskeletal defects in immunodeficiency. Immunological reviews. 2013;256(1):282-99.

Simon A, Kremer H, Wevers R, Scheffer H, De Jong J, Van der Meer J, et al. Mevalonate kinase deficiency Evidence for a phenotypic continuum. Neurology. 2004;62(6):994-7.

van der Burgh R, ter Haar NM, Boes ML, Frenkel J. Mevalonate kinase deficiency, a metabolic autoinflammatory disease. Clinical immunology. 2013;147(3):197-206.

Zhang S. Natural history of mevalonate kinase deficiency: a literature review. Pediatric Rheumatology. 2016;14(1):30.

Feldmann Jm, Prieur A-M, Quartier P, Berquin P, Certain S, Cortis E, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. The American Journal of Human Genetics. 2002;71(1):198-203.

Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant EP, et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity. 2006;24(3):317-27.

Kubota T, Koike R. Cryopyrin-associated periodic syndromes: background and therapeutics. Modern rheumatology. 2010;20(3):213-21.

Hoffman HM, Wanderer AA. Inflammasome and IL-1β-mediated disorders. Current allergy and asthma reports. 2010;10(4):229-35.

Finetti M, Omenetti A, Federici S, Caorsi R, Gattorno M. Chronic infantile neurological cutaneous and articular (CINCA) syndrome: a review. Orphanet journal of rare diseases. 2016;11(1):167.

Punzi L, Furlan A, Podswiadek M, Gava A, Valente M, De Marchi M, et al. Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review. Autoimmunity Reviews. 2009;8(3):228-32.

Rosé CD, Doyle TM, McIlvain-Simpson G, Coffman JE, Rosenbaum JT, Davey MP, et al. Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. The Journal of rheumatology. 2005;32(2):373-5.

Kanazawa N. Presence of a sporadic case of systemic granulomatosis syndrome with a CARD15 mutation. J Invest Dermatol. 2004;122:851-2.

Martin TM, Zhang Z, Kurz P, Rose CD, Chen H, Lu H, et al. The NOD2 defect in Blau syndrome does not result in excess interleukin‐1 activity. Arthritis & Rheumatology. 2009;60(2):611-8.

Brydges S, Kastner D. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Current Concepts in Autoimmunity and Chronic Inflammation: Springer; 2006. p. 127-60.

Caso F, Galozzi P, Costa L, Sfriso P, Cantarini L, Punzi L. Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. RMD open. 2015;1(1):e000097.

Rosé CD, Pans S, Casteels I, Anton J, Bader-Meunier B, Brissaud P, et al. Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes. Rheumatology. 2014;54(6):1008-16.

Pulliero A, Fazzi E, Cartiglia C, Orcesi S, Balottin U, Uggetti C, et al. The Aicardi–Goutieres syndrome. Molecular and clinical features of RNAse deficiency and microRNA overload. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2011;717(1):99-108.

Crow YJ, Rehwinkel J. Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Human molecular genetics. 2009;18(R2):R130-R6.

Crow YJ, Hayward BE, Parmar R, Robins P, Leitch A, Ali M, et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nature genetics. 2006;38(8):917.